Solitary Plasmacytoma of the Breast: A Case of an Uncommon Breast Neoplasm.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
04
2023
revised:
15
05
2023
accepted:
27
05
2023
medline:
12
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Plasmacytoma is a rare cancer that originates from a single plasma cell and is characterized by the abnormal proliferation of monoclonal plasma cells. It is typically localized in a single area of the body, most commonly in the bone or soft tissue. Solitary plasmacytoma can be further classified as either solitary plasmacytoma of bone (SPB) or solitary extramedullary plasmacytoma (SEP or EMP). Diagnosis may be delayed in symptomatically silent plasmacytomas, but early diagnosis and prompt treatment are crucial for the management of this disease. The mean age for patients with plasmacytoma varies depending on the specific type of plasmacytoma, but generally, it is more common in older adults. Soft tissue plasmacytomas are uncommon, and plasmacytomas manifesting within the breast are extremely rare, especially when they are not a manifestation of multiple myeloma (MM). This report presents a case of SEP of the breast in a 79-year-old female patient. This rare disease needs to be studied further in terms of long-term survival and disease progression to MM. By raising awareness and understanding of plasmacytoma, we aim to improve outcomes and quality of life for patients affected by this disease.
Identifiants
pubmed: 37303483
doi: 10.1155/2023/9622042
pmc: PMC10257539
doi:
Types de publication
Case Reports
Langues
eng
Pagination
9622042Informations de copyright
Copyright © 2023 Sean McCormack et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Baillieres Clin Haematol. 1995 Dec;8(4):705-19
pubmed: 8845568
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Cancer. 1980 Feb 15;45(4):647-52
pubmed: 6153562
J Clin Oncol. 2011 Oct 1;29(28):3805-12
pubmed: 21900099
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221111773
pubmed: 35850540
Curr Treat Options Oncol. 2002 Jun;3(3):255-9
pubmed: 12057071
Leukemia. 2009 Feb;23(2):215-24
pubmed: 19020545
PLoS One. 2019 Jul 23;14(7):e0219857
pubmed: 31335866
Acta Radiol. 2010 Jun;51(5):498-504
pubmed: 20429767
Cancer. 1999 Jun 1;85(11):2305-14
pubmed: 10357398
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1685-1717
pubmed: 33285522
World J Surg Oncol. 2004 Aug 31;2:29
pubmed: 15339332
BJR Case Rep. 2020 Sep 29;6(2):20190131
pubmed: 33029381
Adv Anat Pathol. 2020 May;27(3):114-163
pubmed: 32205473
Case Rep Med. 2016;2016:6595610
pubmed: 26925106
J Hematol Oncol. 2018 Jan 16;11(1):10
pubmed: 29338789
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Diagn Pathol. 2011 Dec 19;6:123
pubmed: 22182738
Br J Haematol. 2004 Mar;124(6):717-26
pubmed: 15009059
Am Soc Clin Oncol Educ Book. 2016;35:e418-23
pubmed: 27249749
Blood. 2006 Sep 15;108(6):1979-83
pubmed: 16741249
Medicine (Baltimore). 1976 May;55(3):217-38
pubmed: 1272069
BMC Cancer. 2016 Oct 8;16(1):777
pubmed: 27717354
AJR Am J Roentgenol. 2006 Mar;186(3):821-7
pubmed: 16498114
Pediatr Dermatol. 2014 Nov-Dec;31(6):e120-1
pubmed: 25424220
J Radiol Case Rep. 2020 Dec 31;14(12):14-23
pubmed: 33717400
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514